Fidelity Investments’s Biocept, Inc. BIOC Stock Holding History

Fidelity Investments’s Portfolio BIOC Stock Details BIOC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1	Closed	-$7	–	5674
2023 Q1	$7	Buy	+1	New	+$14	﹤0.01%	5204
2022 Q4	–	Hold	0	–	–	–	5650
2022 Q3	–	Hold	0	–	–	–	5563
2022 Q2	–	Hold	0	–	–	–	5669
2021 Q4	–	Hold	0	–	–	–	5130
2021 Q3	–	Hold	0	–	–	–	5253
2020 Q3	–	Hold	0	–	–	–	4107
2020 Q2	–	Hold	0	–	–	–	4319

Other funds holding BIOC

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fidelity Investments's BIOC Position: Q2 2023 in Review

Fidelity Investments sold out of Biocept, Inc. (BIOC) in Q2 2023, closing a stake of 1 share — an estimated $7 sold.

Fidelity Investments first reported a position in BIOC in Q1 2023 and held it in 1 quarter. The position peaked at $7 in Q1 2023. 11 funds tracked by Wall St. Rank hold BIOC as of Q2 2023.

Fidelity Investments reported no remaining Biocept, Inc. position as of Q2 2023 after selling out during the quarter.
Fidelity Investments sold 1 Biocept, Inc. share in Q2 2023, an estimated $7.
Fidelity Investments first reported a position in Biocept, Inc. in Q1 2023 and held it in 1 quarter.
Fidelity Investments's Biocept, Inc. position peaked at $7 in Q1 2023.
11 funds tracked by Wall St. Rank held Biocept, Inc. as of Q2 2023.

Based on Fidelity Investments's 13F filing for Q2 2023, filed 11 Aug 2023.